Alimera (ALIM) fell 29% in Thursday's AH trading after the FDA failed to approve its Iluvien...

Alimera (ALIM) fell 29% in Thursday's AH trading after the FDA failed to approve its Iluvien drug and asked for more info, but Oppenheimer sees the weakness as a buying opportunity and expects Iluvien to eventually be approved.